Perazine
![]() | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
IUPAC name
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.001.435 |
| Chemical and physical data | |
| Formula | C20H25N3S |
| Molar mass | 339.50 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| | |
Perazine (Taxilan) is a moderate-potency typical antipsychotic of the phenothiazine class. It is quite similar to chlorpromazine, and acts as a dopamine antagonist. A 2014 systematic review compared it with other antipsychotic drugs:
| Summary | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| The number, size and reporting of randomized controlled perazine trials are insufficient to present firm conclusions about the properties of this antipsychotic. It is possible that perazine is associated with a similar risk of extrapyramidal side effects as some atypical antipsychotics but this is based on few comparisons of limited power.[1] | ||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||
See also
References
- 1 2 Leucht S, Helfer B, Hartung B (January 2014). "Perazine for schizophrenia". The Cochrane Database of Systematic Reviews. 1 (1): CD002832. doi:10.1002/14651858.CD002832.pub3. PMID 24425538.
External links
- Perazine at the US National Library of Medicine Medical Subject Headings (MeSH)
| Typical |
|
|---|---|
| Disputed | |
| Atypical |
|
| Others |
|
| |
| Classes |
|
|---|---|
| Antidepressants (TCAs and TeCAs) |
|
| Antihistamines |
|
| Antipsychotics |
|
| Anticonvulsants | |
| Others |
|
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
